Drug Trial Radar · NCT07843290
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Aug 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults. The study will check whether JYP0066 cream can reduce eczema signs and symptoms such as redness, itching, dryness, and skin thickening, and whether it is safe and well tolerated. Participants will be randomly assigned to one of four groups: they will apply either 4%, 3%, or 2% JYP0066 cream, or a matching placebo cream, to eczema-affected skin twice a day for 8 weeks. All creams will look the same. This helps the study compare which concentration works best and how safe each one is.
Conditions
- Atopic Dermatitis (AD)
Interventions
JYP0066 4% topical creamDrug
applied twice daily (BID) to affected skin areas for 8 weeks
3% JYP0066 topical creamDrug
applied twice daily (BID) for 8 weeks
2% JYP0066 topical creamDrug
applied twice daily (BID) for 8 weeks
Matching placebo cream (vehicle, no active ingredient)Drug
applied twice daily (BID) for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in EASI score at Week 8Time frame: Baseline to Week 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.